|Bid||0.00 x 400000|
|Ask||0.00 x 400000|
|Day's Range||19.91 - 20.54|
|52 Week Range||11.52 - 22.70|
|PE Ratio (TTM)||96.11|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
I am writing today to help inform people who are new to the stock market and want to learn about Return on Equity using a real-life example. Evotec AG’s (ETR:EVT)Read More...
On June 25, Sanofi and Evotec reached the second milestone of the diabetes business alliance they entered into in August 2015, with a payment of 3 million euros from Sanofi to Evotec after the latter had met “pre-agreed critical success criteria for a potential manufacturing process” for generating human induced pluripotent stem cell-derived beta cells. The deal aims to extend Evotec’s metabolic disease and stem cell-based drug discovery programs and enhance Sanofi’s extensive diabetes research and development pipeline. According to the agreement, Evotec is eligible to receive as much as 300 million euros in milestone-based payments from Sanofi as well as royalties and research payments. To date, the company has received 9 million euros in upfront milestone-based payments and research funding from Sanofi.
On June 15, Sanofi (SNY) and Evotec, a Germany-based drug discovery and development company, signed an agreement to transfer Sanofi’s anti-infectives unit to Evotec for $70 million. Sanofi will also transfer 100 employees to Evotec and licenses for more than ten infectious disease R&D (research and development) pipeline assets.
Evotec AG (ETR:EVT), a life sciences company based in Germany, received a lot of attention from a substantial price increase on the XTRA over the last few months. As aRead More...
Celgene Corporation (NASDAQ: CELG ) — which is recently very much in the news, although for dubious reasons — has struck a partnership with Germany's Evotec AG (ADR) (OTC: EVTCY ), which partners with ...
After looking at Evotec AG’s (XTRA:EVT) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...
The latest earnings announcement Evotec AG’s (XTRA:EVT) released in December 2017 confirmed that the business endured a immense headwind with earnings declining by -11.89%. Below is a brief commentary onRead More...
Evotec AG (XTRA:EVT), a life sciences company based in Germany, saw a significant share price rise of over 20% in the past couple of months on the XTRA. With manyRead More...
Evotec AG’s (XTRA:EVT) most recent return on equity was a substandard 8.96% relative to its industry performance of 9.32% over the past year. EVT’s results could indicate a relatively inefficientRead More...